Qaytarish

Laktatdegidrogenaza (LDH) izofermentlari

Kod:8041|CPT:83615, 83625|LOINC:14804-9, 2536-1, 2539-5, 2542-9, 2545-2, 2548-6

Sinonimlar
Дегидрогеназа молочной кислоты.LD isoenzymesLDH isoenzymeslactic acid dehydrogenaselactic acid dehydrogenase isoenzymeslactate dehydrogenaselactate dehydrogenase isoenzymes
KabiLDH (LD) Fraksiya 1 (LD) Fraksiya 2 (LD) Fraksiya 3 (LD) Fraksiya 4 (LD) Fraksiya 5

Tahlil ma'lumotlari

Tadqiqot usuli

  • Elektroforez
  • Kinetik ultrabinafsha (UV) usul

Kutilayotgan natija topshirish vaqti

1 kun

Maxsus tayyorlik

  • Fast for 12 hours before the blood draw.
  • Avoid strenuous exercise and emotional stress during the 30 minutes before collection.
  • Do not smoke for 30 minutes prior to collection.

Qanday foydalanish

Laktatdegidrogenaza (LD) izofermentlari (LDH yoki sut kislotasi degidrogenazasi izofermentlari) tahlili hujayra shikastlanishining keng qamrovli ko‘rsatkichi bo‘lib xizmat qiladi va izofermentlar taqsimotini baholash orqali umumiy LDH oshishining kelib chiqishini aniqlashtiradi. LD1 ustun bo‘lgan naqshlar, ayniqsa LD1 > LD2 inversiyasi, miokard shikastlanishi, megaloblastik anemiya, gemolitik anemiya va, kamroq hollarda, buyrak infarktini qo‘llab-quvvatlaydi. LD5 ning oshishi jigar kasalligi yoki skelet mushagi shikastlanishidan dalolat beradi. Izomorfik naqsh — ustun fraksiyasiz umumiy LDHning oshishi — neoplaziya, kardiorespirator kasalliklar, gipotireoz, infeksion mononuklyoz, yallig‘lanish holatlari, uremiya va to‘qima nekrozi bilan bog‘liq bo‘lishi mumkin. O‘tkir ko‘krak og‘rig‘ini baholashda LDH izofermentlari kreatin kinaza‑MB va yurak troponiniga nisbatan kechroq oshadi; kechikkan LD1 > LD2 “flip” klinik belgilar bilan birga talqin qilinganda miokard infarktini qo‘llab-quvvatlashi mumkin. Test, shuningdek, gemolizni, jigar va buyrak kasalliklarini, mushak kasalliklarini baholashda va davolash jarayonida ayrim malign neoplaziyalarni monitoring qilishda yordam beradi.

Cheklovlar

LDH rux tutuvchi hujayra ichki ferment bo‘lib, subbirlik tarkibi va to‘qimalarda taqsimlanishi bilan farqlanadigan besh izofermentdan tashkil topgan. LD1 asosan miokard va miyada ustun; LD1 LD2 bilan birga eritrotsitlar, trombotsitlar va buyrak po‘stlog‘ida yuqori miqdorda uchraydi. LD3 o‘pka, taloq, qalqonsimon bez, oshqozon osti bezi, buyrak usti bezlari va limfotsitlarda boy. LD4 LD3 bilan ustma-ust keladi va granulotsitlar, platsenta hamda erkak jinsiy hujayralarida ham mavjud. LD5 jigar va skelet mushagini xarakterlaydi. Sog‘lom shaxslar zardobida fraksional faollikning odatiy ketma-ketligi: LD2 > LD1 > LD3 > LD4 > LD5. To‘qima shikastlanishi umumiy LDHni oshiradi va fraksional naqshni o‘zgartiradi. LD1:LD2 inversiyasi (“flip”) miokard infarktini qo‘llab-quvvatlaydi, biroq bemorlarning oz qismida inversiya kuzatilmasligi va buning o‘rniga yakka LD1 oshishi mumkin. LD5 ustunligi jigar yoki skelet mushagi kasalliklari bilan kechadi, ayniqsa LD5:LD4 nisbati oshganda. LDH izofermentlarining diagnostik foydasi CK‑MB va troponinga qaraganda kechroq namoyon bo‘ladi va ular bir necha kun ichida bazal darajaga qaytadi; o‘tkir miokard infarkti uchun afzal biomarker yurak troponini hisoblanadi.

O'lchov birligi%
Referens oraliq
MinMaks
01732

Yoshingizga bog'liq

Ko'rsatmalarEvaluation of suspected acute or chronic tissue injury, Workup of systemic illness when the source of elevated total LDH is uncertain, Longitudinal monitoring of chronic conditions, including muscular dystrophies, hemolytic anemias, hepatic and renal disease, and malignancy

Natija og'ishlarining mumkin sabablari

Oshgan daraja

  • amiodarone
  • anabolic steroids
  • anesthetics
  • antibacterial agents
  • antifungal agents
  • aspirin
  • captopril
  • chloramphenicol
  • codeine
  • dapsone
  • diltiazem
  • electroconvulsive therapy (recent)
  • ethanol
  • furosemide
  • hemodialysis
  • interferon alfa
  • interleukin-2
  • isotretinoin
  • methotrexate
  • narcotics
  • nonsteroidal anti-inflammatory drugs
  • penicillamine
  • procainamide
  • prosthetic heart valve
  • simvastatin
  • skin disease
  • strenuous exercise (recent)
  • streptokinase
  • tacrolimus
  • thiopental
  • thrombocytosis
  • valproic acid
  • vasopressin
  • verapamil

Pasaygan daraja

  • amikacin
  • anticonvulsants
  • ascorbic acid
  • cefotaxime
  • dofibrate
  • enalapril
  • hydroxyurea
  • metronidazole
  • naltrexone
  • oxalates
  • urea

Namunangiz talablari

NamunangizZardob
ContainerOltin/yo'lbars qopqoqli probirka (SST, gel ajratgich)
Hajm2 mL (min 1 mL)
Saqlash tayyorlikXona harorati, Sovutilgan

References

Nazarenko GI, Kishkun A. Clinical Evaluation of Laboratory Test Results. Moscow: Meditsina; 2000. p.165-166.

Fischbach FT, Dunning MB. A Manual of Laboratory and Diagnostic Tests. 8th ed. Lippincott Williams & Wilkins; 2008.

Wilson D. McGraw-Hill Manual of Laboratory and Diagnostic Tests. 1st ed. McGraw-Hill; 2007. pp.347-348.